Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
First-in-human trial naar oraal vectorvaccin tegen hiv-1
dec 2018 | HIV, Vaccinatie, Virale infecties